RadNet, Inc. reports recurring developments in outpatient diagnostic imaging, digital health, and radiology technology. The company operates owned and managed imaging centers that provide MRI, CT, PET/CT, mammography, ultrasound, X-ray, fluoroscopy, nuclear medicine, and related procedures for physicians and patients across U.S. markets.
RadNet news commonly covers financial results, imaging-center procedure volumes, guidance updates, joint ventures, acquisitions, and customer or technology collaborations. Its Digital Health segment includes DeepHealth, which provides radiology information technology, AI-powered health informatics, clinical AI applications, patient engagement tools, operational AI, teleradiology services, and related products for the diagnostic imaging industry.
RadNet (NASDAQ: RDNT) and DeepHealth reported results from the ASSURE study, the largest U.S. real-world analysis of AI-driven breast cancer screening, published in Nature Health on Nov 17, 2025. The study evaluated >579,000 women across 109 community imaging sites and found the AI-powered workflow in RadNet’s Enhanced Breast Cancer Detection (EBCD) program produced a 21.6% increase in cancer detection rate vs state-of-the-art 3D mammography, a 15% increase in positive predictive value, and maintained recall rates within ACR guidelines. Benefits were consistent across populations, including >150,000 Black women and a 22.7% boost for women with dense breasts.
RadNet (NASDAQ:RDNT) DeepHealth and GE HealthCare announced an expanded strategic collaboration on Nov 12, 2025 to broaden AI-powered imaging across modalities and geographies. The plan extends a 2024 mammography partnership to a worldwide breast solution, integrates GE ultrasound with DeepHealth Thyroid Suite for automated nodule detection and reporting, and proposes combining DeepHealth TechLive™ remote scanning with GE ultrasound to enable remote supervision and simplify workflows.
RadNet cited up to 30% exam time reduction and > 94% acceptance of Thyroid AI reports on 4,070+ nodules as performance highlights. Both companies will present demonstrations at RSNA Nov 30–Dec 4, 2025.
RadNet (NASDAQ: RDNT) announced the acquisition of CIMAR UK on November 11, 2025, integrating CIMAR into RadNet’s DeepHealth digital health unit to advance AI-powered, connected imaging-based care across the UK and Europe.
CIMAR provides cloud-native image management across >50% of NHS trusts and 80% of UK private hospital groups; an existing DeepHealth–CIMAR partnership already connects DeepHealth’s AI lung solution to >90% of NHS Lung Cancer Screening Program sites. UK data show a shift to earlier detection (76% detected at earlier stages vs 29% historically).
RadNet (NASDAQ: RDNT) reported Q3 2025 Revenue $522.9M (+13.4% YoY) and Adjusted EBITDA $84.9M (+15.2% YoY), with margin expansion of 26 bps to 16.2%.
Digital Health Revenue rose 51.6% to $24.8M; Digital Health Adjusted EBITDA was $3.5M. Aggregate advanced imaging volumes increased 13.0% (same-center +9.9%).
Balance sheet: $804.7M cash and Net Debt to Adjusted EBITDA ~1.0x. Company raised full-year 2025 guidance: Imaging Center revenue now $1,900–$1,930M, Imaging Center Adjusted EBITDA $276–$284M, Digital Health revenue $85–$95M.
RadNet (NASDAQ: RDNT) acquired the assets of Alpha RT to expand DeepHealth’s remote-imaging capabilities, combining Alpha RT’s staffing, training and AI safety monitoring with DeepHealth’s FDA-cleared TechLive™ remote scanning technology.
The combined portfolio supports remote MR, CT, PET and ultrasound scanning from an integrated command center, offers AI-driven MRI safety alerts, vendor-agnostic remote MRI technologist staffing, an MRI Tech Aide Certification program, and intelligent scheduling. Pilot metrics cited: a 0.06% recall rate on remote scans and a 42% reduction in MRI room closures.
RadNet (NASDAQ: RDNT) announced its Investor Day agenda for Tuesday, November 11, 2025, to be held 9:00 a.m.–2:30 p.m. ET at Nasdaq MarketSite in New York City with a live webcast and archived replay available.
Titled “On the Leading Edge of Healthcare: Advancing Imaging Through Innovation and Technology,” the event includes opening remarks and a financial overview, clinical spotlights, digital health and services presentations, demonstrations of DeepHealth AI products (Breast Suite, Diagnostic Suite, TechLive™, Patient Engagement), and two Q&A sessions. In-person attendance is by invitation; investors may request consideration via rdnt@addo.com.
RadNet (NASDAQ: RDNT) will host an Investor Day at the Nasdaq MarketSite in New York City on Tuesday, November 11, 2025 from 9:00 a.m. to 2:30 p.m. ET. The event will include presentations by senior executives and physician leaders on strategic priorities, market opportunities, and the company’s innovation roadmap.
In-person attendance is by invitation and requires registration. A live webcast and replay, plus slide presentations, will be available via www.radnet.com/investor-day and the company’s Investor Relations page.
RadNet (NASDAQ: RDNT) will host a conference call to discuss its third quarter 2025 financial results on Monday, November 10, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. Investors can join by phone at 844-826-3035 (U.S.) or 412-317-5195 (international).
There will be simultaneous and archived webcasts at https://viavid.webcasts.com/starthere.jsp?ei=1740003&tp_key=5e6a1fc906. An archived phone replay will be available via 844-512-2921 (U.S.) or 412-317-6671 (international) using passcode 10204112.
RadNet (NASDAQ:RDNT), a leading provider of diagnostic imaging services, announced its participation in the upcoming Jefferies Healthcare Services Conference. Dr. Howard Berger, President and CEO, and Mark Stolper, Executive Vice President and CFO, will present on September 29, 2025, at 1:50 PM Central Time in Nashville, TN.
Investors can access the presentation through a simultaneous webcast, which will also be archived for future viewing, available on the company's website under the "About RadNet" section and through the provided webcast link.
RadNet (NASDAQ: RDNT), a leading provider of outpatient diagnostic imaging services, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's senior management team, including CEO Dr. Howard Berger, CFO Mark Stolper, and EVP Mital Patel, will present on September 9th, 2025, at 4:50 PM ET at the Sheraton New York Times Square Hotel.
The presentation will be accessible through a simultaneous webcast and will also be archived for future viewing through the provided webcast link.